FindTrial
Sign In

NovoLog

DRUG8 trials

Sponsors

Nastech Pharmaceutical Company, Inc., University of Florida, Massachusetts General Hospital, Stanford University, Boston Medical Center

Conditions

Diabetes MellitusDiabetes Mellitus, Type 1Insulin AspartPharmacodynamicsPharmacokineticsType 1 DiabetesType 1 Diabetes MellitusType 2 Diabetes Treated With Insulin

Phase 1

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study
CompletedNCT05184868
Arecor LimitedDiabetes Mellitus, Type 1
Start: 2022-01-03End: 2022-09-09Updated: 2022-09-13

Phase 2

A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients
CompletedNCT00624767
Nastech Pharmaceutical Company, Inc.Diabetes Mellitus
Start: 2008-03-31End: 2008-05-31Updated: 2008-05-20
Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas
TerminatedNCT03262116
Massachusetts General HospitalType 1 Diabetes Mellitus
Start: 2019-03-19End: 2019-07-23Updated: 2022-12-09
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers
CompletedNCT05539872
Amphastar Pharmaceuticals, Inc.Pharmacodynamics, Pharmacokinetics
Start: 2022-08-22End: 2023-01-30Updated: 2026-03-05
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers
RecruitingNCT07560150
Amphastar Pharmaceuticals, Inc.Insulin Aspart, Pharmacodynamics, Pharmacokinetics
Start: 2026-04-06End: 2026-06-01Target: 60Updated: 2026-04-30

Phase 3

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus
CompletedNCT04460326
Boston Medical CenterType 2 Diabetes Treated With Insulin
Start: 2020-12-07End: 2023-05-27Updated: 2024-03-19

Phase 4

Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy
CompletedNCT03554486
Stanford UniversityDiabetes Mellitus, Type 1
Start: 2018-07-23End: 2019-03-30Updated: 2021-08-18

Unknown Phase

Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia
CompletedNCT01621776
University of FloridaType 1 Diabetes
Start: 2011-06-30End: 2012-08-31Updated: 2013-09-13